EP2968317A4 - THERAPEUTIC TARGETING OF THE MTOR PATHWAY IN NEUROLOGICAL DISEASES - Google Patents

THERAPEUTIC TARGETING OF THE MTOR PATHWAY IN NEUROLOGICAL DISEASES

Info

Publication number
EP2968317A4
EP2968317A4 EP14762460.5A EP14762460A EP2968317A4 EP 2968317 A4 EP2968317 A4 EP 2968317A4 EP 14762460 A EP14762460 A EP 14762460A EP 2968317 A4 EP2968317 A4 EP 2968317A4
Authority
EP
European Patent Office
Prior art keywords
neurological diseases
mtor pathway
therapeutic targeting
targeting
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14762460.5A
Other languages
German (de)
French (fr)
Other versions
EP2968317A1 (en
Inventor
Maria Karayiorgou
Sander Markx
Joseph A Gogos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP2968317A1 publication Critical patent/EP2968317A1/en
Publication of EP2968317A4 publication Critical patent/EP2968317A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14762460.5A 2013-03-15 2014-03-17 THERAPEUTIC TARGETING OF THE MTOR PATHWAY IN NEUROLOGICAL DISEASES Ceased EP2968317A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361852150P 2013-03-15 2013-03-15
US201361794606P 2013-03-15 2013-03-15
US201361803977P 2013-03-21 2013-03-21
US201361918307P 2013-12-19 2013-12-19
PCT/US2014/030693 WO2014145857A1 (en) 2013-03-15 2014-03-17 TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE

Publications (2)

Publication Number Publication Date
EP2968317A1 EP2968317A1 (en) 2016-01-20
EP2968317A4 true EP2968317A4 (en) 2016-12-28

Family

ID=51538117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14762460.5A Ceased EP2968317A4 (en) 2013-03-15 2014-03-17 THERAPEUTIC TARGETING OF THE MTOR PATHWAY IN NEUROLOGICAL DISEASES

Country Status (2)

Country Link
EP (1) EP2968317A4 (en)
WO (1) WO2014145857A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003801A2 (en) 2011-06-29 2013-01-03 The Trustees Of Columbia University In The City Of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
CN104829610B (en) * 2014-06-20 2017-03-15 中国科学院合肥物质科学研究院 A kind of novel cloth Shandong tyrosine kinase inhibitor
CN112237629A (en) * 2019-07-16 2021-01-19 温州市中心医院 Application of ERK/mTOR signal pathway regulator in preparing medicine for improving or treating neurodevelopmental disorder related diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062681A2 (en) * 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
US20100298304A1 (en) * 2009-01-16 2010-11-25 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
CN102488687A (en) * 2011-12-22 2012-06-13 武汉大学 Application of rapamycin to preparation of medicament for treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659851C (en) * 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
US20140018354A9 (en) * 2009-07-23 2014-01-16 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062681A2 (en) * 2008-10-30 2010-06-03 University Of South Florida Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
US20100298304A1 (en) * 2009-01-16 2010-11-25 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
CN102488687A (en) * 2011-12-22 2012-06-13 武汉大学 Application of rapamycin to preparation of medicament for treating schizophrenia

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ATSUSHI SATO ET AL: "Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex", NATURE COMMUNICATIONS, vol. 3, 18 December 2012 (2012-12-18), United Kingdom, pages 1292, XP055320205, ISSN: 2041-1723, DOI: 10.1038/ncomms2295 *
BALLOU; LIN, J. CHEM. BIOL., vol. 1, 2008, pages 27 - 36 *
DELIA M. TALOS ET AL: "The Interaction between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway", PLOS ONE, vol. 7, no. 5, 2 May 2012 (2012-05-02), pages e35885, XP055320394, DOI: 10.1371/journal.pone.0035885 *
GARCÍA-ECHEVERRÍA CARLOS: "Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 15, 2010, pages 4308 - 4312, XP028851573, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.05.099 *
GUERTIN, SABATINI, SCIENCE SIGNALLING, vol. 2, no. 67, PE24, 21 April 2009 (2009-04-21), pages 1 - 6 *
JULIE MEFFRE ET AL: "5-HT 6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia", EMBO MOLECULAR MEDICINE, vol. 4, no. 10, 1 October 2012 (2012-10-01), Weinheim, pages 1043 - 1056, XP055285724, ISSN: 1757-4676, DOI: 10.1002/emmm.201201410 *
KER YU ET AL: "Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 2, 15 January 2010 (2010-01-15), pages 621 - 631, XP002646841, ISSN: 0008-5472, [retrieved on 20100112], DOI: 10.1158/0008-5472.CAN-09-2340 *
PETER T. TSAI ET AL: "Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice", NATURE, vol. 488, no. 7413, 1 July 2012 (2012-07-01), United Kingdom, pages 647 - 651, XP055320065, ISSN: 0028-0836, DOI: 10.1038/nature11310 *
POWELL; DELGOFFE: "The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism", IMMUNITY, vol. 33, no. 3, 1 September 2010 (2010-09-01), US, pages 301 - 311, XP055591065, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2010.09.002 *
Q. LIU ET AL: "Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR", CANCER RESEARCH, vol. 73, no. 8, 22 February 2013 (2013-02-22), US, pages 2574 - 2586, XP055286271, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-1702 *
SAXTON; SABATINI, CELL, vol. 168, September 2017 (2017-09-01), pages 960 - 974 *
See also references of WO2014145857A1 *
THEOHARIDES THEOHARIS C: "Is a Subtype of Autism an Allergy of the Brain?", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 35, no. 5, 27 April 2013 (2013-04-27), pages 584 - 591, XP028543857, ISSN: 0149-2918, DOI: 10.1016/J.CLINTHERA.2013.04.009 *
WANDER ET AL., J. CLINICAL INVENTIGATION, vol. 121, 2011, pages 1231 - 1241 *
ZHOU MIOU ET AL: "mTOR Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons", NEURON, CELL PRESS, US, vol. 77, no. 4, 20 February 2013 (2013-02-20), pages 647 - 654, XP028983424, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2012.12.033 *

Also Published As

Publication number Publication date
WO2014145857A1 (en) 2014-09-18
EP2968317A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
IL274646A (en) Integrated continuous manufacturing of therapeutic protein drug substances
CY2019033I2 (en) MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF HYPERPLASTIC DISEASES
IL269511A (en) New therapeutic approaches to treat Parkinson's disease
HUE039864T2 (en) Pharmaceutical preparations for the treatment of CFTR-mediated diseases
HUE043171T2 (en) 1-Arylcarbonyl-4-oxypiperidine Compounds useful in the treatment of neurodegenerative diseases
HRP20182069T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ALZHEIMER DISEASE
PT2882441T (en) TREATMENT OF IMMUNITY AND INFLAMMATORY DISEASES
EP2838909A4 (en) TARGETED THERAPEUTIC AGENTS
IL235512B (en) History of phenylbenzamide for use in the treatment of aquaporin-mediated diseases
LT2796132T (en) NEUROLOGICAL DISORDERS THERAPY ON THE BASIS OF BACLOFEN AND ACAMPLE
EP2819703A4 (en) TREATMENT OF PAIN
EP2906208A4 (en) THERAPEUTIC TREATMENT
IL229017B (en) Oxidative diseases of the retina
IL233313A0 (en) The composition of a new carbohydrate drug for the treatment of human diseases
PT2872497T (en) CROMANILO DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES
EP2872120A4 (en) TARGETED THERAPEUTIC NANOPARTICLES
PL2582366T3 (en) Pharmaceutical combination for the treatment of pain
IL233639B (en) Preparations and methods for the treatment of diseases and liver disorders
IL235768A0 (en) Pharmaceutical preparations and treatment of inflammation of the nipples
PL2922576T3 (en) METHODS OF ADMINISTRATION AND EVALUATION OF NITROGEN-TAKING DRUGS FOR THE TREATMENT OF Hepatic ENCEFALOPATI
EP2912186A4 (en) TREATMENT TARGETING PLATELETS
IL234606B (en) Innovative methods and compounds for the treatment of diseases
LT2958624T (en) TREATMENT OF TRANSPLANTANT DISEASE IN TRANSPLANTANT PATIENTS
SMT201700103B (en) THERAPEUTIC AND DIAGNOSTIC TARGET
IL235874A0 (en) Treatment of ocular inflammatory diseases using laquinimod

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101AFI20160727BHEP

Ipc: A61K 31/519 20060101ALI20160727BHEP

Ipc: A61P 25/00 20060101ALN20160727BHEP

Ipc: A61K 31/4745 20060101ALI20160727BHEP

Ipc: C07D 471/04 20060101ALI20160727BHEP

Ipc: A61P 25/24 20060101ALN20160727BHEP

Ipc: A61K 31/5377 20060101ALI20160727BHEP

Ipc: A61P 25/18 20060101ALN20160727BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALN20161122BHEP

Ipc: A61K 31/497 20060101AFI20161122BHEP

Ipc: C07D 471/04 20060101ALI20161122BHEP

Ipc: A61P 25/00 20060101ALN20161122BHEP

Ipc: A61K 31/5377 20060101ALI20161122BHEP

Ipc: A61K 31/4745 20060101ALI20161122BHEP

Ipc: A61K 31/519 20060101ALI20161122BHEP

Ipc: A61P 25/18 20060101ALN20161122BHEP

17Q First examination report despatched

Effective date: 20180810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20201009